NCT00591370View on ClinicalTrials.gov

Phase II Trial of Extended-Dosing Temozolomide in Patients With Melanoma

PHASE2CompletedINTERVENTIONAL

Enrollment

51

Participants

Timeline

Start Date

January 31, 2005

Primary Completion Date

June 30, 2008

Study Completion Date

June 30, 2008

Conditions

Melanoma

Interventions

DRUG

Temozolomide (TMZ)

One group treatment study

Trial Locations (1)

10065

Memorial Sloan-Kettering Cancer Center, New York

Sponsors

Collaborators (1)

Schering-Plough

All Listed Sponsors

collaborator

Schering-Plough

INDUSTRY

lead

Memorial Sloan Kettering Cancer Center

OTHER